Press Releases

Crescendo Biologics to present at the 2024 AACR Annual Meeting

View PDF

Crescendo Biologics to participate in upcoming investor and partnering conferences

View PDF

Crescendo Biologics announces publication in Neoplasia of preclinical tumour penetration data supporting CB307

View PDF

Crescendo Biologics announces first U.S. patients dosed in expanded Phase 1b clinical trial of CB307 for patients with mCRPC

View PDF

Crescendo Biologics to participate in upcoming investor and partnering conferences

View PDF

Crescendo Biologics wins significant European Patent Office ruling related to the engineering of immunoglobulin technology

View PDF

Crescendo Biologics secures $32M and announces expansion of CB307 Phase 1b trial in PSMA+ solid tumours

View PDF

Crescendo Biologics announces presentation at AACR 2023

View PDF

Crescendo Biologics is category winner for Biopharma and Vaccines
in 2023 UK DIT Life Sciences Innovator Showcase

View PDF

Crescendo Biologics to participate in upcoming investor conferences

View PDF

Crescendo Biologics to participate in upcoming investor conferences

View PDF

Crescendo Biologics’ CEO shortlisted for ‘Private Company CEO of the Year’ at the 2022 European Lifestars Awards

View PDF

Crescendo Biologics shortlisted for ‘Most Impactful UK Deal’ at 2022 OBN Awards

View PDF

Crescendo Biologics announces nomination of second proprietary clinical candidate from immuno-oncology Humabody VH development portfolio

View PDF

Crescendo Biologics to participate in upcoming investor conferences

View PDF

Crescendo Biologics to participate in upcoming conferences

View PDF

Crescendo Biologics announces presentations at AACR 2022

View PDF

Crescendo Biologics to participate in upcoming investor conferences

View PDF

BioNTech and Crescendo Biologics announce global collaboration to develop multi-specific precision immunotherapies

View PDF

Crescendo Biologics announces publication of data for CB213, a PD-1xLAG-3 multi-specific Humabody®, in the British Journal of Cancer

View PDF

Crescendo to attend upcoming investor conferences

View PDF

Crescendo Biologics wins “Best Established Biotech Company” at the 2021 OBN Awards

View PDF

Crescendo Biologics announces that Zai Lab has achieved proof-of-concept for ZL-1102 (Humabody®, CB001) in a Phase 1b clinical trial in psoriasis patients View PDF
Crescendo Biologics announces prestigious new collaboration with The Institute of Cancer Research, London View PDF
Crescendo to participate in upcoming investor conferences View PDF

Crescendo to participate in upcoming investor conferences 

View PDF

Crescendo to participate in upcoming investor conferences View PDF
Crescendo Biologics announces initiation of Phase 1 study of CB307 in patients with advanced, PSMA-positive solid tumours View PDF
Crescendo Biologics further strengthens leadership team with appointment of Dr Michael Booth as Chief Financial Officer View PDF
Crescendo to participate in upcoming investor conferences View PDF
Crescendo Biologics and IAG partner to support the clinical development of CB307 with advanced imaging analysis technology View PDF
New data demonstrate that Humabodies® are highly effective in generating monospecific and bispecific CAR-T cells to target solid tumours View PDF

Crescendo Biologics expands its ongoing collaboration with Takeda View PDF

Crescendo Biologics enters pre-clinical collaboration with Orano Med to explore Targeted Alpha Therapy View PDF
Crescendo Biologics and Cancer Research UK sign Clinical Development Partnership to develop CB213, a novel bispecific Humabody® therapeutic View PDF
Crescendo Biologics appoints Dr Kenji Hashimoto as Chief Medical Officer View PDF
Publication in Cancer Research demonstrates Crescendo Biologics’ Humabody® VH therapeutics outperform conventional antibodies in vivo View PDF
New Biotechnology publication validates Crescendo Biologics’ platform as it moves towards the clinic View PDF

Crescendo Biologics presenting at key industry events during October 2019

View PDF

Crescendo Biologics reaches fifth milestone in its strategic collaboration with Takeda View PDF
Crescendo Biologics to collaborate with world-leading oncology groups at the University of Oxford and the University of Surrey View PDF
Crescendo Biologics strengthens leadership team with appointment of ex-GSK Stewart Kay, as Chief Business Officer View PDF 
Crescendo Biologics’ second oncology-targeted Humabody® licensed by Takeda View PDF 
Crescendo Biologics to present preclinical data on its lead Humabody® candidate, CB307, at the Cell Engager Therapeutics Summit 2019 View PDF

Crescendo Biologics announces prestigious academic research collaborationsView PDF

Crescendo Biologics achieves another milestone in its strategic collaboration with Takeda View PDF
Crescendo awarded with EU patent on immunoglobulin libraries from transgenic animals View PDF
Crescendo broadens patent protection in US on VH-producing lambda chain KO mice View PDF
Theodora Harold to be appointed new CEO at Crescendo Biologics View PDF
Crescendo Biologics wins in “Life Science Innovation” category at the Business Weekly Awards 2019 View PDF
Crescendo Biologics announces Humabody® evaluation in CAR-T by Takeda View PDF
Crescendo Biologics announces early licensing by Takeda of first oncology-targeted Humabody® View PDF
Crescendo Biologics wins “Biotech Company of the Year” at the Cambridge Independent Science and Technology Awards 2018 View PDF
Crescendo Biologics appoints SVP CMC, Dr Richard Williams, and new CDMO partner, as it advances towards the clinic View PDF
Crescendo Biologics shortlisted for Private Financing Deal of the Year at 2018 Scrip Awards View PDF
Crescendo Biologics shortlisted for Lifestars Awards 2018 View PDF
Crescendo Biologics shortlisted for Cambridge Independent Science and Technology Awards 2018 View PDF
Crescendo Biologics strengthens its management with the appointment of Dr Pavel Pisa as Chief Medical Officer View PDF
Crescendo Biologics reaches technical milestone for a second target in strategic collaboration with Takeda View PDF
Crescendo Biologics appoints clinical development expert, Dr Igor Matushansky, as Non-Executive Director View PDF
Crescendo Biologics appoints Eva-Lotta Allan as Non-Executive Director View PDF
Zai Lab and Crescendo Biologics enter exclusive worldwide license agreement for innovative protein therapeutics for inflammatory indications View PDF
Crescendo Biologics Ltd. raises $70 Million (€57 Million) in Series B Financing View PDF
Crescendo Biologics reaches first major milestone in strategic collaboration with Takeda View PDF
Crescendo Biologics appoints Dani Bach as Non-Executive Director View PDF
Crescendo Biologics to present poster at AACR Annual Meeting 2018, Chicago View PDF
Crescendo Biologics’ Colette Johnston to present at 11th Annual Proteins & Antibodies Congress, London View PDF
Crescendo Biologics’ James Legg to present at 4th Annual Crown Bioscience Cambridge Symposium View PDF
Crescendo Biologics to attend 12th Annual BIO-Europe Spring 2018, Amsterdam View PDF
Crescendo Biologics to attend 36th Annual J.P. Morgan Healthcare Conference 2018, San Francisco View PDF
Crescendo Biologics’ Brian McGuinness to present at IBC Antibody Engineering & Therapeutics Conference View PDF
Crescendo Biologics Wins “Licensing Deal of the Year” at the Scrip Awards 2017 View PDF
Crescendo Biologics’ CEO, Peter Pack to attend Jefferies Healthcare Conference View PDF
Crescendo Biologics’ CSO to present at Biotech and Money Investival Showcase View PDF
Crescendo Biologics’ CEO, Peter Pack, to present at 9th Annual PEGS Europe View PDF
Crescendo Biologics is pleased to announce that it has been shortlisted for ‘Licensing Deal of the Year’ at the Scrip Awards 2017.
Crescendo Biologics Wins “Emerging Star of the Year” Award at the European Mediscience Awards View PDF
Crescendo Biologics Appoints Edward J. Stewart as Chief Business Officer View PDF
Crescendo Biologics shortlisted for Biotech and Money 2017 Awards View PDF
Crescendo Biologics to present at BIO International and ICCS in San Diego, US View PDF
Crescendo Biologics nominated for Mediscience Emerging Star Award View PDF
Crescendo Biologics Appoints Philip Bland-Ward as Chief Scientific Officer View PDF
Crescendo Biologics’ CEO, Peter Pack to present and participate in panel at Biotech and Money 2017 View PDF
Crescendo Biologics partners with software-provider, Genedata, on next-generation immuno-oncology and ADC programs. View PDF
Crescendo Biologics Appoints Theodora Harold as Chief Financial Officer View PDF
Crescendo Biologics and Takeda Enter Collaboration for Humabody®-based Therapeutics Worth up to $790m View PDF
Crescendo strengthens IP portfolio with U.S. patent to transgenic mouse platform for generating Humabody® therapeutics. View PDF
Key Oncology Data on Humabody® Drug Conjugates. View PDF
Crescendo Biologics Appoints Dr Barbara Fleck as Head of Intellectual Property. View PDF
Crescendo Appoints New Chairman View PDF
Crescendo Biologics Launches New Strategy & Appoints Dr Peter Pack as CEO View PDF
Crescendo Biologics Expands ADC Programmes with Innovate UK Funding Award: Biomedical Catalyst Award to Support Development of New Therapies to Target Prostate Cancer View PDF
Crescendo Biologics to Present at Biotech Showcase™ 2015 View PDF
Crescendo Biologics’ Receives Further Investment from Astellas Venture Management to Develop Novel Humabody™ Therapeutics Targeting Immune Checkpoint Inhibitors View PDF
Crescendo Biologics Recognised at OBN Annual Awards Dinner View PDF
EMBL Ventures Invests £2M ($3.3M) in a Second Close of Crescendo Biologics’ Series A Financing View PDF
Crescendo Biologics Wins Cambridge Business Innovation Award View PDF
Crescendo Biologics Raises £17.5M ($28M) in Series A Financing View PDF
Crescendo Biologics Announces the Crescendo Mouse View PDF
Crescendo Biologics Extends IP Protection for Mouse Knock Out Technology View PDF
Crescendo Biologics Extends IP Protection for Transgenic Mouse Technology View PDF
Crescendo Biologics Appoints Matthew Roe as Chief Business Officer View PDF
Crescendo Biologics' Mouse Knockout Patent Upheld View PDF
Mike Romanos Appointed as CEO of Crescendo Biologics View PDF
Crescendo Biologics Announces First ‘Triple Knockout’ Mouse View PDF
Clive Dix Appointed as Chairman of Crescendo Biologics View PDF
Crescendo Biologics Raises £4.5 million in Seed Funding Led by Sofinnova Partners View PDF
Mike Romanos Appointed as CSO of Crescendo Biologics View PDF